Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 known ✓ | Q99500 | 1/20 | 0.40 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.61 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.50 |
| ▸ | SLC22A12 | Q96S37 | 6/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 4/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425967 | 0.98 | IDO1 (0.63) | IDO1TRPV4SLC22A12GRM4KDM4E | |
| SCHEMBL3833327 | 0.82 | SLC22A12 (0.50) | IDO1TRPV4SLC22A12GRM4KDM4E | |
| SCHEMBL6125193 | 0.78 | IDO1 (0.54) | IDO1TRPV4SLC22A12GRM4S1PR3 | |
| SCHEMBL15357415 | 0.77 | IDO1 (0.53) | IDO1TRPV4SLC22A12GRM4S1PR3 | |
| Hydrochloric Acid SCHEMBL5057770 | 0.77 | TRPV4 (0.50) | IDO1TRPV4CYP11B2 | |
| Hydrochloric Acid SCHEMBL425553 | 0.77 | ABCG2 (0.43) | IDO1SLC22A12KDM4ES1PR3ALDH1A1 | |
| SCHEMBL16854124 | 0.76 | IDO1 (0.55) | IDO1TRPV4SLC22A12GRM4S1PR3 | |
| SCHEMBL19557916 | 0.76 | IDO1 (0.51) | IDO1TRPV4SLC22A12GRM4S1PR3 | |
| Hydrochloric Acid SCHEMBL629175 | 0.74 | MAPT (0.53) | IDO1KDM4ENPC1POLBMAPT | |
| SCHEMBL3623834 | 0.74 | TRPV4 (0.52) | IDO1TRPV4CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2937348-B1 | PROCESS FOR THE PREPARATION OF A COMPOUND USED AS MINERALOCORTICOID RECEPTOR ANTAGONIST | KBP BIOSCIENCES PTE LTD (SG) | 2021-09-08 | — | — | EP | claimed |
| US-9809589-B2 | Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor | KBP BIOSCIENCES CO., LTD. (CN) | 2017-11-07 | — | — | US | claimed |
| US-20150336950-A1 | CRYSTAL FORM OF COMPOUND USED AS MINERALOCORTICOID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | KBP BIOSCIENCES CO., LTD. (CN) | 2015-11-26 | — | — | US | claimed |
| CN-105026391-A | Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor | KBP BIOSCIENCES CO LTD | 2015-11-04 | — | — | CN | claimed |
| EP-2937348-A1 | CRYSTAL FORM OF COMPOUND USED AS MINERALOCORTICOID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | KBP Biosciences Co., Ltd. (CN) | 2015-10-28 | — | — | EP | claimed |
| EP-3954688-A1 | CRYSTAL FORMS OF COMPOUND USED AS MINERALOCORTICOID RECEPTOR ANTAGONIST AND METHODS FOR THEIR PREPARATION | KBP BIOSCIENCES PTE. LTD. (SG) | 2022-02-16 | — | — | EP | disclosed |
| EP-2937348-B1 | PROCESS FOR THE PREPARATION OF A COMPOUND USED AS MINERALOCORTICOID RECEPTOR ANTAGONIST | KBP BIOSCIENCES PTE LTD (SG) | 2021-09-08 | — | — | EP | disclosed |
| US-9809589-B2 | Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor | KBP BIOSCIENCES CO., LTD. (CN) | 2017-11-07 | — | — | US | disclosed |
| US-9468635-B2 | Fused ring compound for use as mineralocorticoid receptor antagonist | KBP BIOSCIENCES CO., LTD. (CN) | 2016-10-18 | — | — | US | disclosed |
| US-20150336950-A1 | CRYSTAL FORM OF COMPOUND USED AS MINERALOCORTICOID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | KBP BIOSCIENCES CO., LTD. (CN) | 2015-11-26 | — | — | US | disclosed |
| CN-105026391-A | Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor | KBP BIOSCIENCES CO LTD | 2015-11-04 | — | — | CN | disclosed |
| EP-2937348-A1 | CRYSTAL FORM OF COMPOUND USED AS MINERALOCORTICOID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | KBP Biosciences Co., Ltd. (CN) | 2015-10-28 | — | — | EP | disclosed |
| WO-2008053300-A1 | PYRAZOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| CN-1072210-C | 1-phenyl-3-pyrazolecarboxamides active on neurotensin receptors | SANOFI SYNTHELABO (FR) | 2001-10-03 | — | — | CN | disclosed |
| US-6172239-B1 | PSYCHOLOGICAL, NERVOUS SYSTEM DISORDERS | SANOFI (FR) | 2001-01-09 | — | — | US | disclosed |
| US-5965579-A | ANTAGONISTS OF THE NEUROTENSIN RECEPTORS; INCREASING AFFINITY FOR HUMAN NEUROTENSIN RECEPTORS | SANOFI (FR) | 1999-10-12 | — | — | US | disclosed |
| US-5939449-A | NOVEL COMPOUNDS HAVING HIGH AFFINITY FOR THE NEUROTENSIN RECEPTORS | SANOFI (FR) | 1999-08-17 | — | — | US | disclosed |
| US-5936123-A | COMPOUNDS SUCH AS 3-ISOPROPYL-4-HYDRAZINOBENZOIC ACID AND ITS SALTS | SANOFI (FR) | 1999-08-10 | — | — | US | disclosed |
| US-5925661-A | NERVOUS SYSTEM DISORDERS | SANOFI (FR) | 1999-07-20 | — | — | US | disclosed |
| US-5723483-A | NEUROTENSIN ANTAGONIST, HYPOTENSIVE AGENTS AND FOR NEUROPSYCHIATRIC DISORDERS | SANOFI (FR) | 1998-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336950-A1 | CRYSTAL FORM OF COMPOUND USED AS MINERALOCORTICOID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | NR3C2, REN, MC2R | S1PR3 1065/4885GAA 4613/4885IDO1 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.